Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Group 1 - Lyell Immunopharma (NASDAQ: LYEL) has made significant progress with its CD19/CD20 CAR-T cell therapy targeting patients with aggressive 3rd-line + Large B-Cell Lymphoma (LBCL) [2] - The company is part of the Biotech Analysis Central service, which provides in-depth analysis of various pharmaceutical companies [2] Group 2 - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] - The service is available for $49 per month, with a yearly plan offering a 33.50% discount at $399 per year [1]